Boston Scientific is a global leader in medical devices, excelling in both MedSurg and Cardiovascular segments with consistent, industry-beating growth. Q1 2024 was a record quarter, with 21% YoY revenue growth, strong margins, and EPS beating expectations by $0.08. Organic growth and strategic acquisitions fuel BSX's expansion, supported by a diverse portfolio and active venture investments.
In the latest trading session, Boston Scientific (BSX) closed at $104.50, marking a -0.01% move from the previous day.
Boston Scientific Corporation (NYSE:BSX ) Bernstein 41st Annual Strategic Decisions Conference Call May 28, 2025 8:01 AM ET Company Participants Michael Mahoney - Chairman and Chief Executive Officer Kenneth Stein - Senior Vice President and Global Chief Medical Officer Conference Call Participants Lee Hambright - Sanford C. Bernstein & Co., LLC Lee Hambright Okay.
22 Jul 2025 (49 Days) Date | | - Cons. EPS | - EPS |
22 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | - Cons. EPS | - EPS |
24 Oct 2024 Date | | - Cons. EPS | - EPS |
23 Oct 2024 Date | | - Cons. EPS | - EPS |
22 Jul 2025 (49 Days) Date | | - Cons. EPS | - EPS |
22 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | - Cons. EPS | - EPS |
24 Oct 2024 Date | | - Cons. EPS | - EPS |
23 Oct 2024 Date | | - Cons. EPS | - EPS |
Medical - Devices Industry | Healthcare Sector | Mr. Michael F. Mahoney CEO | XMUN Exchange | US1011371077 ISIN |
US Country | 53,000 Employees | - Last Dividend | 6 Nov 2003 Last Split | 18 May 1992 IPO Date |
Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices used in a variety of interventional medical specialties. Having begun its operations in 1979, the company has grown to serve a diverse range of medical needs through its two primary segments: MedSurg and Cardiovascular. With its headquarters in Marlborough, Massachusetts, Boston Scientific is committed to improving patient health by providing cutting-edge solutions that address complex medical conditions and enhance the quality of life for patients worldwide.